Morgan Stanley raised the firm’s price target on Kymera Therapeutics (KYMR) to $127 from $73 and keeps an Overweight rating on the shares. Phase 1b data for its STAT6 degrader, KT-621, in atopic dermatitis “beat the high bar set by investors and company management,” says the analyst, who is adjusting the firm’s model for Phase 2 development probability of success.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating
- Promising Potential of Kymera Therapeutics’ KT-621: A Buy Rating Justified by Strong Clinical Trial Results
- Kymera Therapeutics price target raised to $125 from $98 at Piper Sandler
- Kymera Therapeutics price target raised to $110 from $80 at Citi
- Kymera Therapeutics price target raised to $112 from $71 at BofA